BACKGROUND: Mesothelium vascular cell adhesion molecule-1 (VCAM-1) expression in the metastatic epithelial ovarian cancer (EOC) microenvironment is induced by tumor and mediates tumor cell invasion. VCAM-1 imaging suggests expression during treatment is an indicator of platinum resistance. Here, we assess the potential prognostic significance of mesothelium VCAM-1 expression and prospectively evaluate whether soluble VCAM-1 (sVCAM-1) is a surrogate for mesothelium expression. METHODS: A retrospective review of EOC patients was performed to evaluate outcomes with mesothelium VCAM-1 expression determined by immunohistochemistry of peritoneum or omentum specimens. A prospective cohort of EOC patients was identified and followed through primary treatment. Serum for sVCAM-1 evaluation, which was performed via enzyme-linked immunosorbent assay, was collected before surgery or neoadjuvant chemotherapy and at each treatment cycle. Peritoneal specimens were obtained during debulking to assess mesothelial VCAM-1 expression. RESULTS: A retrospective review identified 54 advanced-stage EOC patients. Patients expressing mesothelium VCAM-1 had shortened overall survival (44 vs 79 months, P 5 0.035) and progression-free survival (18 vs 67 months, P 5 0.010); the median time to platinum resistance was 36 months for VCAM-1-expressing patients and not yet determined for the VCAM-1-negative group. In our prospective observational cohort, 18 EOC patients completed primary treatment; 3 were negative for mesothelium VCAM-1 expression, and sVCAM-1 did not vary between groups. CONCLUSIONS: Mesothelium VCAM-1 expression is negatively associated with progression-free and overall survival in EOC. This is especially compelling in light of previous data suggesting that persistent VCAM-1 expression during treatment is an indicator of platinum resistance. Our pilot study had insufficient cases to determine whether sVCAM-1 would substitute for mesothelium expression. Cancer 2017;123:977-84.
INTRODUCTION
Despite years of developing aggressive surgical techniques and novel adjuvant therapy strategies, epithelial ovarian cancer (EOC) remains the most lethal of the gynecologic malignancies.
1 Because the likelihood of developing robust whole population screening programs in the near future is low, 2, 3 it is imperative that the mechanisms of peritoneal seeding and tumor spread are better defined to direct therapeutic strategies. Furthermore, identification of specific biomarkers of disease response and recurrence may aid in the development of more personalized treatment strategies earlier in the course of treatment.
Current primary treatment strategies for EOC combine surgical resection and systemic platinum-based chemotherapy. The order and approach to these treatment modalities have been modified over the last several decades with some promise; in general, 80% of women will experience a response to treatment with the majority achieving remission. [4] [5] [6] Unfortunately, approximately 80% of patients will experience a recurrence within 24 months of completion of primary therapy. Not surprisingly, the time to recurrence dramatically impacts prognosis and future response to therapy; however, currently no reliable method or biomarker exists to identify patients most likely to recur in short order or those unlikely to respond to primary therapy from the outset. Therefore, while the exact combination and timing may vary, the approach to primary chemotherapy and surgery for EOC is somewhat standard for all patients. Attempts to predict time to recurrence, the utility of maintenance chemotherapy, or identification of early signs of recurrent disease have failed to identify any reliable biomarkers of disease behavior, and as a result, have not provided a significant improvement in survival. 7, 8 We identified vascular cell adhesion molecule-1 (VCAM-1) as a regulator of ovarian cancer peritoneal metastasis. 9 VCAM-1 is consistently overexpressed on the mesothelium, a single cell layer of mesothelial cells lining the peritoneal cavity and surrounding organs within it, in the setting of advanced disease, 10 which represents the majority of EOC patients at diagnosis. Furthermore, the frequency of VCAM-1 expression increases with the extent of peritoneal tumor involvement; however, not all patients with peritoneal metastases display VCAM-1 positivity. 10 In our previous assessment of advanced-stage EOC patients, the majority of those lacking mesothelium VCAM-1 expression had previously been exposed to neoadjuvant chemotherapy (NACT), and our preclinical models employing VCAM-1 targeted imaging demonstrated that expression during treatment is an indicator of platinum resistance. 10 Taken together, our findings implicate VCAM-1 as a potential marker of platinum responsiveness.
While mechanistic studies of the impact of VCAM-1 expression in the EOC microenvironment are ongoing, the clinical impact of its presence as a potential therapeutic target and a molecular indicator of treatment sensitivity is compelling. In the current study, we employed a retrospective cohort of ovarian cancer patients to assess whether mesothelium VCAM-1 expression is associated with prognosis, thus further strengthening our hypothesis that it is a potential biomarker of platinum responsiveness in EOC. Because mesothelium VCAM-1 expression segregates advanced-stage ovarian cancer patients who respond to standard-of-care chemotherapy from those who do not, and VCAM-1 is also found as a soluble form (sVCAM-1) in serum that has been investigated as a component of a biomarker panel for the detection of EOC, 11 we investigated whether sVCAM-1, like its mesothelium counterpart, would also reflect the presence of advanced disease burden and serve as a less invasive surrogate for mesothelium expression. We report the results of a prospective observational cohort study investigating serum sVCAM-1 levels in EOC patients over the course of standard treatment as compared with healthy volunteer controls.
PATIENTS AND METHODS
The University of Virginia Institutional Review Board approved all aspects of the study.
Retrospective Review
Retrospective review of patients undergoing surgery for EOC at the University of Virginia Health System from 1999 to 2008 identified 54 advanced-stage patients from whom clinical records and paraffin-embedded tissue blocks of omentum or peritoneum were obtained. Hematoxylin and eosin-stained sections were evaluated to ensure the presence of mesothelial cells. The Biorepository Tissue Research Facility at the University of Virginia stained additional sections immunohistochemically for VCAM-1 as described previously using antihuman VCAM-1 antibodies (Abcam) according to the manufacturer's instructions. 9, 10 Expression was scored as high if >50% and a contiguous string of 10 mesothelial cells displayed membranous staining with 3 1 intensity or low if <50% or fewer than 10 contiguous cells stained with 3 1 intensity. Slides were read and scored by a single pathologist (K.A.A.) at our institution. Expression classification was evaluated with respect to clinical data including demographics, tumor stage, tumor histology, treatment options, and outcomes including overall survival, progression-free survival, and time to platinum resistance.
Prospective Serum VCAM-1 Detection

Subject identification
EOC patients were identified at the time of diagnosis and, after consent, were assigned to 1 of 2 cohorts on the basis of treatment approach, which was determined at the discretion of the treating physician: primary debulking surgery 1 adjuvant chemotherapy (PDS) or neoadjuvant chemotherapy 1 interval debulking (NACT). A third cohort of healthy control subjects with no active gynecologic problem, autoimmunity, or known inflammatory condition was included to obtain nondisease sVCAM-1 levels. These patients were not matched on the basis of age. EOC patients received a standard 6-cycle platinum/taxanebased chemotherapy regimen. Those receiving NACT underwent interval debulking surgery after the third cycle of chemotherapy and completed 3 additional cycles postoperatively. Serum was collected at the time of routine monthly chemotherapy laboratory tests for each treatment cycle and at 1 month and 3 months after treatment. Peritoneum and omentum samples were collected from each patient at the time of primary or interval surgery. Healthy volunteer control participants consented to 4 separate monthly blood draws for sVCAM-1 assessment.
Sample size
The prospective observational pilot study set target sample size at 24 subjects, 9 for each cohort of ovarian cancer Original Article patients (18 total) and 6 healthy control subjects. Based on previous data assessing sVCAM-1 levels in gastric cancer patients versus controls (12) , the total sample of 24 subjects would achieve approximately 90% power to detect a difference in baseline sVCAM-1 expression of at least 242 using Dunnett's multiple comparison test (with control) at a 4% significance level, which corresponded to the minimum difference observed in sVCAM-1 expression and the largest observed within group standard deviation of 78. 12 Thirty newly diagnosed EOC patients were identified and consented to participate in this observational study. Twelve patients were excluded: 3 patients had a final diagnosis that was not consistent with EOC, 1 patient declined further treatment, 1 patient died of disease during primary therapy, and 7 patients elected to receive chemotherapy closer to home due to geographic constraints. Eighteen patients were enrolled for NACT (n 5 9) or PDS (n 5 9), based on their clinical presentation and discretion of the treating physician. All patients completed primary treatment.
Specimen collection and evaluation
Serum (10 mL/draw) was collected in red top silica clot activator tubes with a conventional stopper, assigned a unique identifier, transported to the Biorepository and Tissue Research Facility at the University of Virginia within 1 hour of collection, and stored at 280 8C. Enzyme-linked immunosorbent assay of sVCAM-1 was performed by the Center for Research in Reproduction Ligand Assay and Analysis Core at the University of Virginia. Tissue specimens were handled according to institutional pathology protocol. Peritoneum and omentum specimens not necessary for diagnosis were paraffin-embedded and stained for VCAM-1 expression as described above.
Statistical considerations
Analysis of variance using Dunnett's multiple comparison test was used to assess differences in serum sVCAM-1 at baseline among the 3 groups. Repeated measure models were used to assess the pattern of change in serum sVCAM-1 levels over time in the cancer patients and to determine whether patterns differed by cohort for the prospective observational study. Time to event distributions were estimated using the Kaplan-Meier method, and a log-rank test was used to test for differences.
RESULTS
Retrospective Cohort Analysis
Fifty-four advanced-stage (primarily III and IV) EOC patients were identified retrospectively; 3 were excluded for ambiguous VCAM-1 staining and 1 was excluded for lack of follow-up data (Table 1) . Median age, disease stage, and histology were all consistent with the literature. Optimal cytoreduction, which we defined as leaving no more than 1 cm of residual tumor, portends a favorable prognosis for advanced-stage ovarian cancer patients. 4, 5 Within this cohort, 76% of patients were optimally debulked and had a median survival of 74 months compared with 23 months for the 22% of patients who were suboptimally debulked (Fig. 1A) . Sixty-five percent of the patients received primary debulking surgery (PDS) followed by adjuvant chemotherapy; the remaining 35% received neoadjuvant chemotherapy (NACT) with interval debulking surgery. The most commonly cited reason for pursuing NACT in this setting was medical comorbidity/poor functional status. Survival analysis was performed on the basis of treatment approach (Fig. 1B) . In keeping with the evolving literature regarding treatment approaches in ovarian cancer, 13, 14 there was no evidence of a survival difference between patients receiving NACT compared with PDS in this cohort (Fig. 1B) .
Peritoneum or omentum tissue samples were evaluated for membranous VCAM-1 staining on mesothelial cells. We found that the mesothelium VCAM-1 expression level was either high (31) or absent; intermediate levels of expression were not observed (see Supporting Fig.  1 ). Therefore, expression was scored as positive or negative. Additionally, half of the tissue blocks contained tumor cells, and VCAM-1 expression did not depend on their presence (data not shown). We reported previously that patients receiving NACT were less likely to express VCAM-1 on the mesothelium 10 (Table 1) . Indeed, among the patient demographic information presented in Table 1 , treatment approach was the only factor that associated significantly with VCAM-1 expression. Preclinical data demonstrate that VCAM-1 expression reflects chemoresponsiveness and resistance to platinum-based therapy. 10 Because platinum resistance has a known negative impact on survival of EOC, we evaluated whether baseline mesothelium VCAM-1 expression itself was associated with overall prognosis. Within this cohort, overall survival was significantly less in patients expressing mesothelium VCAM-1 (median of 44 months vs 79 months; log-rank P 5 .035) with a minimum of 5 years of follow-up (Fig.  2) . The 5-year survival for VCAM-1-negative patients was 55% compared with 37% for VCAM-1-positive patients. Moreover, progression-free survival was shorter for VCAM-1-positive patients than for the negative group (median of 18 months vs 67 months; log-rank P 5 .01) (Fig. 3 ) in the subset of 41 patients where progression or lack of progression information was known.
To further assess the influence of VCAM-1 expression on chemosensitivity, we analyzed patients on the basis of primary platinum resistance. Information regarding platinum responsiveness was available for 35 patients in this cohort. Development of platinum resistance was determined from the date of surgery irrespective of the treatment approach and included all patients regardless of their initial response to treatment (i.e., platinum-refractory, platinum-resistant, and development of resistance after initial sensitivity). The median time to develop platinum resistance was 36 months for patients with positive mesothelium VCAM-1 expression and not yet reached for those who were negative (P 5 .052) (Fig. 4) . Together, these observations support the notion that mesothelium expression of VCAM-1 at the time of debulking surgery identifies patients who are less likely to respond favorably to standard-of-care treatment and have an unfavorable prognosis.
Prospective sVCAM-1 Pilot Study
The pilot prospective observational study was designed as described to obtain preliminary data on 1) whether Figure 1 . Survival analysis based on treatment. Kaplan-Meier plots show survival in months of (A) patients with (dark teal) or without (light teal) optimal cytoreduction and (B) patients receiving neoadjuvant chemotherapy (NACT, dark teal) versus upfront surgery (light teal). A log-rank test was used to evaluate significance. The number of subjects at risk is indicated. P values are shown on each graph. Kaplan-Meier plots show survival in months of patients who were positive (light teal) or negative (dark teal) for VCAM-1 expression on the mesothelium. A log-rank test was used to evaluate significance. The number of subjects at risk is indicated below the graph.
sVCAM-1 levels differed between malignant and benign conditions and 2) whether the levels among women with malignancies were reflective of mesothelium expression of VCAM-1. Based on our retrospective findings indicating that mesothelium VCAM-1 expression was inversely associated with outcome, we sought to identify a less invasive surrogate that could be followed easily and be potentially clinically actionable over a standard EOC treatment course. Baseline characteristics are shown in Table 2 . The median age of all 18 EOC patients was 61 years with median ages of 60 and 64 for the PDS and NACT groups, respectively ( Table 2 ). The cited reason for utilization of NACT in this study was medical comorbidity and the general performance status of the patient. Use of NACT at our institution at the time of this study was approximately 20% and was generally reserved for women believed to be at high risk of surgical morbidity/mortality at the time of diagnosis. Ninety-four percent of patients were stage IIIC or greater, and 72% of patients had highgrade serous disease (data not shown). A similar distribution of optimal versus suboptimal cytoreduction was obtained for both groups (Table 2) , and all patients received treatment consisting of a combination of platinum and taxane.
Mesothelium VCAM-1 staining was obtained for 7 PDS and 8 NACT patients; 1 patient in the PDS group and 2 NACT patients were negative for VCAM-1 ( Table  2 ). The mean sVCAM-1 concentration for PDS (813 6 58.8 ng/mL) and NACT (906.1 6 102.6 ng/mL) groups taken at the time of surgery did not differ from each other or control (764.5 6 84.5 ng/mL) (Dunnett's multiple comparison test, P 5 0.55) nor did they vary over time (Ftest, P 5 .8) or between groups over time (F-test, P 5 .72) (Fig. 5) . With only 3 patients identified as negative for mesothelium VCAM-1 expression, there were insufficient data to assess the association with sVCAM-1 (Table 2) . Therefore, sVCAM-1 was unable to distinguish women with or without ovarian cancer, and this pilot study was unable to identify sVCAM-1 as a surrogate for mesothelium expression. Moreover, the data indicate a high level of variability in sVCAM-1 measurements over time that should be considered in the design of future studies.
DISCUSSION
We previously identified mesothelium VCAM-1 as an indicator of peritoneal metastasis in which it regulated 
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Cancer ovarian cancer cell invasion. Here, we found that mesothelium expression of VCAM-1 was negatively associated with progression-free and overall survival in EOC. Additionally, patients expressing VCAM-1 developed resistance to platinum agents more rapidly than the lowexpressing cohort. However, our pilot study evaluating sVCAM-1 as a potential surrogate for mesothelium expression was unable to distinguish cancer patients from healthy individuals or correlate serum levels with mesothelium expression. Taken together, these observations provide the first evidence that VCAM-1 expressed in the microenvironment may have prognostic significance for EOC. The a priori goal of our retrospective study was to assess whether there was an association between mesothelium VCAM-1 expression and EOC outcome. The identification of a negative association between expression and progression-free or overall survival among advancedstage EOC patients is compelling. The number of observed events within our patient population guided the decision to limit the number of evaluable characteristics to 3 and ruled out the ability to assess interaction effects. It should be noted that there was a disparity in VCAM-1-negative staining between the retrospective cohort (40%) and our prospective cohort (20%). The lower incidence of VCAM-1-negative staining in our observational study raises the question as to whether NACT truly impacts VCAM-1 expression; however, with only 8 patients analyzed in the prospective group, cross-comparisons between cohorts are less likely to generate meaningful conclusions. Additional larger studies will be necessary to resolve these discrepancies as well as to determine whether mesothelium VCAM-1 expression predicts outcomes and whether it does so independently of other variables, including age at diagnosis, histological subtype, and surgical timing and outcome among others.
Although the incidence of VCAM-1 expression is lower among patients who received NACT and preclinical imaging data in mouse models indicate that mesothelium VCAM-1 expression reflects tumor response to treatment, it is unclear whether VCAM-1 expression changes in EOC patients and what impact changing expression might indicate about prognosis. The pilot prospective observational study evaluating sVCAM-1 over the course of treatment was an attempt to address this issue; however, sVCAM-1 did not segregate malignant versus benign conditions or change significantly over time irrespective of disease status. At the time of study design, there were no clearly defined parameters for serum sVCAM-1 in a normal state of health. Additionally, we observed a higher degree of variability than that reported previously. 12 The inability to monitor mesothelium VCAM-1 expression by measuring sVCAM-1 lends support to develop VCAM-1 targeting imaging probes to monitor expression in EOC patients over the course of treatment.
VCAM-1 has been identified as a prognostic indicator in other disease sites, including gastric, colon, breast, renal, melanoma, non-Hodgkin and Hodgkin lymphoma, and chronic B-cell lymphoma. 12, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Expression of VCAM-1 on the stroma in colon cancer portended an unfavorable outcome and was inversely related to sVCAM-1 levels. 16 However, others have shown that elevated sVCAM-1 is associated with increased tumor size and metastasis 15 and predicts recurrence in colorectal cancer. 18 Tumor cell expression of VCAM-1 is associated with increased survival in renal cell carcinoma 25 and a worse outcome in ovarian cancer. 26 While VCAM-1 expression on tumor cells was not observed (data not shown), our data linking mesothelium VCAM-1 expression to poor survival are consistent with the reported association between tumor expression and outcome. 26 Importantly, mesothelial cells are not under the evolutionary pressure of genetically mutable tumors; VCAM-1 expression is not affected by exposure to platinum agents. 10 It is unclear whether tumor cell expression responds to treatment.
Increased sVCAM-1 levels have been linked with increased tumor burden in colon cancer and chronic B-cell lymphoma 17, 22 or poor survival in gastric, breast, melanoma, and non-Hodgkin and Hodgkin lymphoma. 15, [19] [20] [21] 23, 24 One small cohort study of 36 ovarian cancer patients identified significantly elevated sVCAM-1 in 5 Figure 5 . Serum sVCAM-1 concentration. Levels of sVCAM-1 were determined from serum of ovarian cancer patients undergoing PDS (light blue squares) or NACT (dark blue triangles) taken just before each chemotherapy session (sequences 1-6) and during 3 follow-up visits. VCAM-1 concentration was determined from serum withdrawn from women free of disease at 4 monthly intervals (control, red circles).
patients who died within 11 months of follow-up compared with the 31 who were alive. 27 Another study found no association between sVCAM-1 and outcome among ovarian cancer patients (n 5 50) but identified patients with metastatic disease. 28 The primary objective of our study was to link sVCAM-1 to mesothelium VCAM-1 expression with the expectation that it could serve as a surrogate prognosticator. Several limitations potentially impeded our ability to achieve this objective. Other conditions contribute to sVCAM-1 expression including chronic inflammatory conditions such as atherosclerosis or autoimmune disease. This study did not account for different treatment approaches such as intraperitoneal chemotherapy or the use of bevacizumab, and the sample size was too small to stratify based on additional variables. Additionally, the small sample size restricted our ability to determine whether outcomes such as survival or development of platinum resistance would correlate with sVCAM-1 levels. Although additional studies would be necessary, it is possible that sVCAM-1 would not reflect mesothelium VCAM-1 expression; sVCAM-1 and tissue VCAM-1 expression have not been correlated with other cancers. 16, 21, 22 The ability of mesothelium VCAM-1 expression to identify advanced-stage ovarian cancer patients who are likely to respond to current standard-of-care chemotherapy and discriminate outcomes provides an opportunity to affect clinical management. Whereas up-front treatment options are limited to surgery and platinum/taxane-based chemotherapy, newer drugs including bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, 29 and olaparib, an inhibitor of poly (ADP-ribose) polymerase (PARP), 30 have been approved for recurrent ovarian cancer, and VEGF and PARP inhibitors are currently being tested in multiple clinical trials for upfront treatment and in maintenance therapy. Immunotherapy is another realm of developing therapeutics in EOC. It would be interesting to know whether VCAM-1-expressing patients respond to these classes of drugs.
As the use of NACT evolves, many academic centers are now performing diagnostic laparoscopy before primary cytoreductive surgery to more accurately predict those patients for whom a primary surgical effort will be successful. This procedure allows appropriate triage of patients who cannot have a successful surgery due to disease burden to neoadjuvant therapy, and also allows the collection of a sufficient tumor biopsy for histology as well as next generation sequencing and potentially VCAM-1 measurement. The VCAM-1 results would then allow patients to be appropriately stratified to clinical trials-which, for example, use biologics or immunotherapy to potentially prevent or reverse the development of platinum resistance. 
FUNDING SUPPORT
